Eli Lilly and Company (NYSE:LLY) is NWK Group Inc.’s 4th Largest Position

NWK Group Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,234 shares of the company’s stock after selling 70 shares during the quarter. Eli Lilly and Company accounts for about 5.0% of NWK Group Inc.’s investment portfolio, making the stock its 4th biggest position. NWK Group Inc.’s holdings in Eli Lilly and Company were worth $8,551,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. Silicon Valley Capital Partners acquired a new position in Eli Lilly and Company in the first quarter worth about $25,000. Laffer Tengler Investments bought a new position in Eli Lilly and Company during the 1st quarter worth approximately $33,000. Raleigh Capital Management Inc. grew its position in shares of Eli Lilly and Company by 156.4% in the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after acquiring an additional 61 shares in the last quarter. Activest Wealth Management bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $40,000. Finally, Riggs Asset Managment Co. Inc. raised its position in shares of Eli Lilly and Company by 50.4% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 179 shares of the company’s stock valued at $61,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on LLY shares. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $630.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, November 15th. Citigroup raised their target price on shares of Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Royal Bank of Canada upped their target price on Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Finally, Credit Suisse Group raised their price target on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $557.00.

Eli Lilly and Company Price Performance

NYSE LLY traded up $8.58 on Monday, reaching $600.29. 827,037 shares of the stock traded hands, compared to its average volume of 3,094,083. Eli Lilly and Company has a 12 month low of $309.20 and a 12 month high of $629.97. The company has a market cap of $569.86 billion, a price-to-earnings ratio of 107.54, a P/E/G ratio of 3.57 and a beta of 0.33. The firm’s fifty day simple moving average is $577.98 and its 200 day simple moving average is $509.95. The company has a quick ratio of 0.82, a current ratio of 1.05 and a debt-to-equity ratio of 1.59.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a dividend of $1.13 per share. The ex-dividend date is Tuesday, November 14th. This represents a $4.52 annualized dividend and a yield of 0.75%. Eli Lilly and Company’s dividend payout ratio is currently 81.88%.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 37,660 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total value of $20,590,670,905.00. Following the completion of the sale, the insider now directly owns 100,275,279 shares of the company’s stock, valued at approximately $54,825,684,274,988.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 37,660 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total value of $20,590,670,905.00. Following the sale, the insider now directly owns 100,275,279 shares in the company, valued at approximately $54,825,684,274,988.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Donald A. Zakrowski sold 670 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $571.10, for a total transaction of $382,637.00. Following the sale, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The disclosure for this sale can be found here. Insiders have sold a total of 535,538 shares of company stock valued at $20,881,299,452 over the last three months. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.